A prospective, open-labelled, randomized, multicenter phase II study to evaluate efficacy and safety of Erlotinib vs NP chemotherapy as adjuvant therapy in post radical operation NSCLC patients with EGFR19 or 21 exon mutation

Trial Profile

A prospective, open-labelled, randomized, multicenter phase II study to evaluate efficacy and safety of Erlotinib vs NP chemotherapy as adjuvant therapy in post radical operation NSCLC patients with EGFR19 or 21 exon mutation

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs Erlotinib (Primary) ; Cisplatin; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 19 Oct 2016 Planned End Date changed from 1 Mar 2019 to 1 Oct 2020.
    • 19 Oct 2016 Planned primary completion date changed from 1 Mar 2019 to 1 Oct 2020.
    • 30 Jul 2014 Status changed to completed as reported by Chinese Clinical Trial Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top